A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis

A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis

Abstract Introduction To evaluate the efficacy and safety of sirukumab in giant cell arteritis (GCA). Methods In this multicentre, randomised, double-blind, placebo-controlled, two-part phase 3 trial (NCT02531633; Part A [52-week double-blind treatment]; Part B [104-week follow-up]), patients with G...

Full description

Bibliographic Details
Main Authors: Wolfgang A. Schmidt, Bhaskar Dasgupta, Raashid Luqmani, Sebastian H. Unizony, Daniel Blockmans, Zhihong Lai, Regina H. Kurrasch, Ivana Lazic, Kurt Brown, Ravi Rao
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-08-01
Series:Rheumatology and Therapy
Subjects:
Clinical trial
Corticosteroid taper
Giant cell arteritis
Interleukin-6
Sirukumab
Online Access:https://doi.org/10.1007/s40744-020-00227-2

Internet

https://doi.org/10.1007/s40744-020-00227-2

Similar Items